Nouveautés dans la prise en charge de l’échinococcose alvéolaire [Novelties on the management of alveolar echinococcosis]
Fiche du document
14 juin 2023
- doi: 10.53738/REVMED.2023.19.831.1192
- issn: 1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.53738/REVMED.2023.19.831.1192
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/37314259
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pissn/1660-9379
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_53AEF51B82AF9
info:eu-repo/semantics/embargoedAccess , Restricted: cannot be viewed until 2024-12-14 , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
Hydatid cysts Hydatids Hydatidosis Echinococcal disease Echinococciasis Hydatid diseaseCiter ce document
G.R. Joliat et al., « Nouveautés dans la prise en charge de l’échinococcose alvéolaire [Novelties on the management of alveolar echinococcosis] », Serveur académique Lausannois, ID : 10.53738/REVMED.2023.19.831.1192
Métriques
Partage / Export
Résumé
Alveolar echinococcosis is an endemic parasitosis in Switzerland. This pathology mainly infects the liver and develops similarly as a malignant tumor with its ability to spread into the hepatic parenchyma and its capacity of developing distant lesions via hematogenous dissemination. Treatment is based on complete surgical resection coupled with albendazole treatment. Recently, ex vivo liver resections with auto-transplantation have been shown to be feasible in case of end-stage alveolar echinococcosis. Moreover, new biomarkers such as programmed death-ligand 1 (PD-L1), a protein with immunomodulation property, have shown their potential impact on the treatment and follow-up of patients with alveolar echinococcosis.